Laroche C, Wells F, Coulden R, Stewart S, Goddard M, Lowry E, Price A, Gilligan D
Thoracic Oncology Unit, Papworth NHS Trust, Papworth Hospital, Papworth Everard, Cambridgeshire, UK.
Thorax. 1998 Jun;53(6):445-9. doi: 10.1136/thx.53.6.445.
Surgical resection is the recognised treatment of choice for patients with stage I or II non-small cell lung cancer (NSCLC). In the UK surgical resection rates have remained far lower (< 10%) than those achieved in Europe and the USA (> 20%), despite the recent introduction of fast access investigation units. It remains unclear therefore why UK surgical resection rates lag so far behind those of other countries.
A new quick access two stop investigation service was established at Papworth in November 1995 to investigate all patients presenting to any of three surrounding health districts with suspected lung cancer. Once staging was complete, all patients with confirmed lung cancer were reviewed by a multidisciplinary team which included an oncologist and a thoracic surgeon. Time from presentation to definitive treatment and surgical resection rates were reviewed.
Two hundred and nine (76%) of a total of 275 consecutive patients investigated had confirmed lung cancer (28 small cell, 181 non-small cell). Of the remainder, eight patients (2%) had metastatic disease, four (1%) had other thoracic malignancy (thymoma, mesothelioma), four patients (1%) had benign thoracic tumours, and 50 (18%) had other non-malignant diseases. Of the 181 patients with non-small cell primary lung cancer, 47 (25%) underwent successful surgical resection, of whom 59% had stage I and 21% stage II disease. The failed thoracotomy rate was 11%. Median time from presentation at the peripheral clinic to surgical resection was 5 weeks (range 1-13).
Quick access investigation, high histological confirmation rates, routine CT scanning, and review of every patient with confirmed lung cancer by a thoracic surgeon led to a substantial increase in the successful surgical resection rate. These results support the growing concern that many patients with operable tumours are being denied the chance of curative surgery in our present system.
手术切除是公认的Ⅰ期或Ⅱ期非小细胞肺癌(NSCLC)患者的首选治疗方法。在英国,尽管最近设立了快速通道检查单位,但手术切除率仍远低于欧洲和美国(分别低于10%和高于20%)。因此,目前尚不清楚为何英国的手术切除率远远落后于其他国家。
1995年11月在帕普沃思医院建立了一项新的快速通道两站式检查服务,以对来自周边三个健康区、疑似患有肺癌的所有患者进行检查。一旦分期完成,所有确诊为肺癌的患者均由包括肿瘤学家和胸外科医生在内的多学科团队进行评估。对从就诊到最终治疗的时间以及手术切除率进行了评估。
在连续接受检查的275例患者中,209例(76%)确诊为肺癌(28例小细胞癌,181例非小细胞癌)。其余患者中,8例(2%)患有转移性疾病,4例(1%)患有其他胸部恶性肿瘤(胸腺瘤、间皮瘤),4例(1%)患有良性胸部肿瘤,50例(18%)患有其他非恶性疾病。在181例原发性非小细胞肺癌患者中,47例(25%)成功接受了手术切除,其中59%为Ⅰ期疾病,21%为Ⅱ期疾病。开胸手术失败率为11%。从在周边诊所就诊到手术切除的中位时间为5周(范围1 - 13周)。
快速通道检查、高组织学确诊率、常规CT扫描以及胸外科医生对每例确诊肺癌患者的评估,使得成功手术切除率大幅提高。这些结果支持了人们日益增长的担忧,即在我们当前的医疗体系中,许多患有可手术肿瘤的患者被剥夺了接受根治性手术的机会。